Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWJ245)

• Drug Name: ATX-201 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Discontinued in Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMWJ245

Molecule-Related Drug Atlas

Drug(s) Targeting Tubulin (TUB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Vinorelbine	DMVXFYE	Advanced cancer	2A00-2F9Z	Approved	[4]
Cabazitaxel	DMPAZHC	Breast cancer	2C60-2C65	Approved	[5]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Ixabepilone	DM2OZ3G	Breast cancer	2C60-2C65	Approved	[5]
Eribulin	DM1DX4Q	Breast cancer	2C60-2C65	Approved	[5]
Epothilon	DMITJRU	Ovarian cancer	2C73	Phase 3	[7]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
BMS-188797	DML1CK2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
Indibulin	DM6OFJ8	Advanced sarcoma	2A60-2C35	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026557)
• [2] Clinical pipeline report, company report or official report of Kythera Biopharmaceuticals.
• [3] Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
• [4] Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
• [5] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [6] Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
• [7] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [8] Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
• [9] Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
• [10] 2011 Pipeline of ZioPharm.